Evidence map›Paper›PMID 41880063›Full record

ArticleInternational journal of clinical oncology2026

Prognostic value of the modified Glasgow Prognostic Score and Prognostic Nutritional Index in prostate cancer treated with cabazitaxel.

Takuma Kato, Yoichiro Tohi, Atsushi Takamoto, Ryutaro Shimizu, Kei Daizumoto, Satoshi Katayama, Keita Kobayashi, Hirofumi Morinaka, Kenichi Nishimura, Hideo Fukuhara and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Takuma KatoDepartment of Urology, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. kato.takuma@kagawa-u.ac.jp.ORCID http://orcid.org/0000-0003-2047-496X
Yoichiro TohiDepartment of Urology, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.ORCID http://orcid.org/0000-0003-3884-8915
Atsushi TakamotoDepartment of Urology, Fukuyama City Hospital, Hiroshima, Japan.
Ryutaro ShimizuDepartment of Urology, Faculty of Medicine, Tottori University, Tottori, Japan.
Kei DaizumotoDepartment of Urology, Faculty of Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.ORCID http://orcid.org/0009-0004-9007-435X
Satoshi KatayamaDepartment of Urology, Medical School, Okayama University, Okayama, Japan.ORCID http://orcid.org/0000-0002-8377-2457
Keita KobayashiDepartment of Urology, Faculty of Medicine and Health Sciences, Yamaguchi University, Yamaguchi, Japan.ORCID http://orcid.org/0000-0001-9279-3156
Hirofumi MorinakaDepartment of Urology, School of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Kenichi NishimuraDepartment of Urology, School of Medicine, Ehime University, Matsuyama, Japan.
Hideo FukuharaDepartment of Urology, Kochi Medical School, Kochi University, Kochi, Japan.
Shuichi MorizaneDepartment of Urology, Faculty of Medicine, Tottori University, Tottori, Japan.ORCID http://orcid.org/0000-0003-0344-5892
Junya FurukawaDepartment of Urology, Faculty of Medicine, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.ORCID http://orcid.org/0000-0001-8974-9218
Motoo ArakiDepartment of Urology, Medical School, Okayama University, Okayama, Japan.ORCID http://orcid.org/0000-0002-3172-2482
Koji ShiraishiDepartment of Urology, Faculty of Medicine and Health Sciences, Yamaguchi University, Yamaguchi, Japan.
Yoshiyuki MiyajiDepartment of Urology, School of Medicine, Kawasaki Medical School, Kurashiki, Japan.ORCID http://orcid.org/0009-0006-9995-565X
Noriyoshi MiuraDepartment of Urology, School of Medicine, Ehime University, Matsuyama, Japan.ORCID http://orcid.org/0000-0002-2229-0948
Keiji InoueDepartment of Urology, Kochi Medical School, Kochi University, Kochi, Japan.
Mikio SugimotoDepartment of Urology, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.ORCID http://orcid.org/0000-0001-9266-782X
Chu-Shikoku Japan Urological Consortium

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe modified Glasgow Prognostic Score (mGPS) and Prognostic Nutritional Index (PNI) are useful prognostic indicators in various cancer types. This study assessed the utility of the mGPS and PNI in predicting survival in men with castration-resistant prostate cancer treated with cabazitaxel.

methodsThis retrospective cohort study analyzed data on patients who received cabazitaxel for castration-resistant prostate cancer between September 2014 and March 2022. The mGPS was scored on a scale of 0-2 points based on the albumin and C-reactive protein (CRP) levels. PNI was calculated using the albumin level and lymphocyte count. The effect of the mGPS and PNI on survival was assessed using the log-rank test and Cox regression.

resultsA total of 215 patients were included in the analysis, of whom 103 (47.9%), 64 (29.8%), and 48 (22.3%) had an mGPS of 0, 1, and 2 points, respectively. The median PNI was 42.2 (interquartile range [IQR]: 38.8-45.9). In a risk model using hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), and mGPS, the median survival was 19, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively. In a risk model using ALP, LDH, and PNI, the overall survival was 18, 13, and 5 months in the low-, intermediate-, and high-risk groups, respectively.

conclusionThe mGPS and PNI are useful prognostic indicators for risk stratification to predict survival in patients with castration-resistant prostate cancer treated with cabazitaxel.

Indexed as

Nutrition AssessmentProstatic Neoplasms, Castration-ResistantTaxoidsAgedAged, 80 and overAntineoplastic AgentsC-Reactive ProteinHumansMaleMiddle AgedPrognosisRetrospective StudiesAntineoplastic AgentscabazitaxelC-Reactive ProteinTaxoidsCastration-resistant prostate cancerInflammationModified Glasgow Prognostic ScoreNutritionPrognostic Nutritional Index

Identifiers

PMID41880063

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.